Literature DB >> 17462006

Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV.

S Walker1, C Fazou, T Crough, R Holdsworth, P Kiely, M Veale, S Bell, A Gailbraith, K McNeil, S Jones, R Khanna.   

Abstract

We have developed a novel diagnostic technology to monitor the human cytomegalovirus (HCMV)-specific CD8+ T-cell responses that is based on the detection of secreted interferon-gamma (IFN-gamma) in the whole blood (referred to as QuantiFERON -CMV). Evaluation of QuantiFERON -CMV in healthy individuals revealed that this technology was at least as sensitive and with some HCMV epitopes more sensitive than the ELISPOT for detecting ex vivo IFN-gamma. Results from QuantiFERON -CMV assays showed 97% (36/37 individuals) agreement with the anti-HCMV serology test in healthy individuals. Furthermore, we also show that this technology can be used to assess HCMV-specific T-cell responses in transplant patients. This study shows that QuantiFERON -CMV is a simple, reproducible, and reliable test for the detection of IFN-gamma in response to HCMV CD8+ T-cell epitopes, and may be a valuable diagnostic test for the detection of HCMV infection and a useful clinical tool for monitoring the immune response in immunosuppressed patients during therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462006     DOI: 10.1111/j.1399-3062.2006.00199.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  53 in total

1.  Modification of the HCMV-specific IFN-γ release test (QuantiFERON-CMV) and a novel proposal for its application.

Authors:  Takahiro Kobayashi; Jun-Ichi Sato; Kazufumi Ikuta; Ryoko Kanno; Kyoko Nishiyama; Tetsuo Koshizuka; Ken Ishioka; Tatsuo Suzutani
Journal:  Fukushima J Med Sci       Date:  2017-06-22

2.  QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy.

Authors:  Anthony S Russell; Luiz Lisboa; Marla F Dos Santos; Deepali Kumar; Atul Humar
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

3.  Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.

Authors:  Angela Chiereghin; Luciano Potena; Laura Borgese; Dino Gibertoni; Diego Squarzoni; Gabriele Turello; Evangelia Petrisli; Giulia Piccirilli; Liliana Gabrielli; Francesco Grigioni; Tiziana Lazzarotto
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

4.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

5.  Post transplant CMV-specific T-cell immune reconstitution in the absence of global T-cell immunity is associated with a high risk of subsequent virus reactivation.

Authors:  S-K Tey; M P Davenport; G R Hill; G A Kennedy; S T Durrant; R Khanna; D Cromer
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483

6.  T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response.

Authors:  Corey Smith; Dillon Corvino; Leone Beagley; Sweera Rehan; Michelle A Neller; Pauline Crooks; Katherine K Matthews; Matthew Solomon; Laetitia Le Texier; Scott Campbell; Ross S Francis; Daniel Chambers; Rajiv Khanna
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

7.  The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.

Authors:  Lynn El Haddad; Ella Ariza-Heredia; Dimpy P Shah; Ying Jiang; Ted Blanchard; Shashank S Ghantoji; Firas El Chaer; Danielle El-Haddad; Amrita Prayag; Lior Nesher; Katy Rezvani; Elizabeth Shpall; Roy F Chemaly
Journal:  J Infect Dis       Date:  2019-02-23       Impact factor: 5.226

8.  Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.

Authors:  María Ángeles Clari; Beatriz Muñoz-Cobo; Carlos Solano; Isabel Benet; Elisa Costa; María José Remigia; Dayana Bravo; Paula Amat; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

9.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

Review 10.  Biomarkers for kidney transplant rejection.

Authors:  Denise J Lo; Bruce Kaplan; Allan D Kirk
Journal:  Nat Rev Nephrol       Date:  2014-01-21       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.